Phase I Studies of Tarceva (erlotinib hydrochloride, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma.
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications CNS cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 09 Mar 2013 Accrual to date is 16% according to United Kingdom Clinical Research Network record.
- 15 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.